Risk Intelligence
Core Model
D+
53 / 100
Insufficient Data
How strong and defensively sound is the company?
Weaker than most covered companies on this measure.
Suggestions
SHC · NASDAQ
SOTERA HEALTH CO
Private betaSector unavailable · Industry unavailable
$18.37
+0.60%
Close on Sep 11, 2026
Insufficient Data
Updated 12/19/2023
Long-term research evidence only. No price targets, no trading signals, no recommendations.
Investment Report Card
SOTERA HEALTH CO
Sector unavailable · Data confidence partial
26 / 100
Rank #636 of 1,152 qualified companies
Top 92% · Not Currently Suggested
Long-Term Potential
Research Model
D
43 / 100
Insufficient Data
Does the business have the characteristics needed to create value over many years?
Weaker than most covered companies on this measure.
Fundamental Momentum
Research Model
D+
53 / 100
Insufficient Data
Is the underlying business getting stronger or weaker?
Weaker than most covered companies on this measure.
Ownership Intelligence
Supplemental Intelligence
C+
67 / 100
Positive disclosed activity
What are important owners actually doing?
Around the middle of the covered universe.
Valuation Intelligence
Research Model
C−
57 / 100
Reasonable
Is today's price reasonable?
Around the middle of the covered universe — and valuation is researched separately from the Suggested Investment Score.
Capital Returns Intelligence
Research Model
F
29 / 100
Limited Capital Returns
How effectively does the company reward shareholders?
Weaker than most covered companies on this measure — and capital returns are researched separately from the Suggested Investment Score.
Why it stands out
- More disclosed holders are new or increasing than reducing or exiting.
What holds it back
No weakening evidence is recorded in today's readings.
Long-term view
SOTERA HEALTH CO scores 43 on Long-Term Potential (D), described by the research model as insufficient data. This describes business characteristics only — it is not a forecast of future returns.
Ownership view
Disclosed ownership evidence reads 67 (C+): Positive disclosed activity. 1 tracked managers disclosed a position in the latest reporting period. Ownership filings are historical disclosures, not signals.
Valuation view
SOTERA HEALTH CO reads 57 out of 100 on Valuation Intelligence, recorded as Reasonable. The stock currently trades below most of its own recent valuation history and below comparable companies. This describes the price being paid relative to the company's financials — it is not a forecast and not a fair value. Valuation Intelligence is a research model and contributes nothing to the Suggested Investment Score or the daily ranking.
Capital returns view
SOTERA HEALTH CO reads 29 out of 100 on Capital Returns Intelligence (Limited Capital Returns), reflecting no measurable direct capital returns. Direct capital returns are limited because the company continues reinvesting most of its cash. Capital Returns Intelligence is a research model and contributes nothing to the Suggested Investment Score or the daily ranking.
What changed
No meaningful recorded changes in the stored history.
Risk Intelligence is a core model, Long-Term Potential, Fundamental Momentum, Valuation Intelligence and Capital Returns Intelligence are research models, and Ownership Intelligence is supplemental descriptive evidence. Valuation Intelligence and Capital Returns Intelligence each contribute 0% to the Suggested Investment Score. Nothing here is a recommendation.
Compare SHC with other companiesResearch Collections
This company does not currently satisfy any collection rule. That is a stored research result, not a judgement about the business.
Browse collectionsAbout a minute to read
The 60-Second Investment Brief
Written from stored research readings only. No hype. No trading signals. Just better evidence.
Why it's interesting
SOTERA HEALTH CO (SHC) scores 26 out of 100 and ranks #636 of 1,152 qualified companies today. That places it in the top 92% of ranked companies. The stored tier for that score is not currently suggested.
Business strength
Risk Intelligence reads 53 out of 100 (D+), recorded as insufficient data. Weaker than most covered companies on this measure.
Long-term opportunity
Long-Term Potential reads 43 out of 100 (D), recorded as insufficient data. Weaker than most covered companies on this measure.
What's improving or weakening
Fundamental Momentum reads 53 out of 100 (D+), recorded as insufficient data. Weaker than most covered companies on this measure.
What important owners are doing
Ownership Intelligence reads 67 out of 100 (C+), recorded as positive disclosed activity. Around the middle of the covered universe.
What kind of price you'd be paying
Valuation currently appears reasonable: Valuation Intelligence reads 57 out of 100 (C−), recorded as Reasonable. SOTERA HEALTH CO reads 57 out of 100 on Valuation Intelligence, recorded as Reasonable. The stock currently trades below most of its own recent valuation history and below comparable companies. This describes the price being paid relative to the company's financials — it is not a forecast and not a fair value. Valuation Intelligence is a research model and contributes nothing to the Suggested Investment Score or the daily ranking.
How the company rewards shareholders
Capital Returns Intelligence reads 29 out of 100 (F), recorded as Limited Capital Returns. SOTERA HEALTH CO reads 29 out of 100 on Capital Returns Intelligence (Limited Capital Returns), reflecting no measurable direct capital returns. Direct capital returns are limited because the company continues reinvesting most of its cash. Capital Returns Intelligence is a research model and contributes nothing to the Suggested Investment Score or the daily ranking.
What could go wrong
No weakening factors are recorded in today's stored readings, and data confidence is partial. Absence of a recorded weakness is not evidence of safety.
Bottom line
No individual layer reaches the strongest band today. Risk Intelligence and Long-Term Potential and Fundamental Momentum remain the main area to watch. Separately from the score, valuation reads reasonable at today's price.
Composite discovery model
Pro Investor Score
Pro Investor Score™
26 / 100
Not Currently Suggested
A 0–100 composite discovery score combining Risk Intelligence, Long-Term Potential, Fundamental Momentum, and Ownership Intelligence. It helps rank qualified companies for further research and does not predict future returns.
- Rank
- #636 of 694
- Percentile
- Top 92%
- Ranking updated
- September 12, 2026
—Rank unchanged. Rank unchanged.
- Risk Intelligence
- 53
- Long-Term Potential
- 43
- Fundamental Momentum
- 53
- Ownership Intelligence
- 67
30% contribution
30% contribution
20% contribution
20% contribution
Ownership Intelligence
67 / 100 · Positive · 20% of the Pro Investor Score
SUPPLEMENTAL / DESCRIPTIVE INTELLIGENCE
Coverage: Partial Coverage
- Elite Investor Activity
- Insufficient Data
- Institutional Activity
- 67 · Positive
- Insider Activity
- Insufficient Data
- Strategic Ownership
- Insufficient Data
50% of Ownership Intelligence · 10% of the total score
No reliably mapped professional-manager filings are stored, so this evidence is unavailable rather than neutral.
20% of Ownership Intelligence · 4% of the total score
Broad institutional evidence from resolved filings is positive.
15% of Ownership Intelligence · 3% of the total score
No discretionary insider transactions are stored for this company, so this evidence is unavailable rather than neutral.
15% of Ownership Intelligence · 3% of the total score
No qualifying major-holder filings are stored, so this evidence is unavailable rather than neutral.
Ownership Intelligence summarizes publicly disclosed activity among professional investment managers, broader institutions, company insiders, and significant strategic owners. It adds context to investment research but is not a validated predictor of future performance. Ownership information is publicly reported with a delay; the latest applicable reporting period is 2026-06-30, publicly disclosed 9/11/2026. Congressional activity is unavailable pending legal review and contributes nothing to this reading.
Why it ranks here
No component ranks in the top quartile of the qualified universe.
What holds it back
Risk Intelligence is less favourable
Defensive characteristics rank below the middle of the qualified universe.
Long-term potential is mid-pack
Long-Term Potential ranks below the qualified median. This remains a research model.
Ownership evidence is not uniformly supportive
The combined disclosed ownership evidence ranks below the qualified median.
Ownership Intelligence — Partial Coverage
Only part of the ownership evidence is available for this company. Missing evidence is left missing rather than replaced with a neutral value.
COMPOSITE DISCOVERY MODEL — RESEARCH STAGE · Data coverage Good. Rankings are recalculated daily using the latest available information. Individual components may update at different frequencies based on when new financial and ownership data becomes available.
Researched separately
Valuation Intelligence 57 · Reasonable
RESEARCH MODEL
Valuation Intelligence is currently researched separately and does not affect the Suggested Investment Score or daily ranking.
Researched separately
Capital Returns Intelligence 29 · Limited Capital Returns
RESEARCH MODEL
Capital Returns Intelligence is researched separately and contributes 0% to the Suggested Investment Score, the daily rank or any ranking event.
Score explanation
Why this company scores the way it does
Four research areas carry fixed weights. Each area is compared against every other eligible company, then weighted. The four contributions below add to 26.1 of the stored score (26.1).
Risk Intelligence
30% of the score · contributes 2.2 points
How strong and defensively sound is the company?
Stands at the 7 percentile of eligible companies · stored reading 53 · 8% of this company’s total score
How financially sturdy the company has been when conditions turned against it.
How this area is measured
Risk Intelligence reads stored balance-sheet strength, historical downside behaviour and the company's price-risk grouping. A stronger reading describes past resilience; it does not protect against future losses.
Full methodologyLong-Term Potential
30% of the score · contributes 7.0 points
Does the business have the characteristics needed to create value over many years?
Stands at the 23 percentile of eligible companies · stored reading 43 · 27% of this company’s total score
Whether the business has the durable characteristics long-term owners look for.
How this area is measured
Long-Term Potential reads durability characteristics such as profitability consistency, cash generation and reinvestment capability over multiple reported periods.
Full methodologyFundamental Momentum
20% of the score · contributes 10.5 points
Is the underlying business getting stronger or weaker?
Stands at the 53 percentile of eligible companies · stored reading 53 · 40% of this company’s total score
Whether the reported business results have been getting stronger or weaker.
How this area is measured
Fundamental Momentum compares recent reported fundamentals with the company's own earlier periods, so improvement or deterioration is measured against its history rather than against a forecast.
Full methodologyOwnership Intelligence
20% of the score · contributes 6.4 points
What are important owners actually doing?
Stands at the 32 percentile of eligible companies · stored reading 67 · 25% of this company’s total score
What large reporting owners have actually been doing with their positions.
How this area is measured
Ownership Intelligence reads public ownership filings: how many tracked reporting owners hold the company, and whether they were adding, holding, reducing or exiting in the latest disclosed period.
Full methodology
What is helping the score
No research area currently stands in the stronger half of eligible companies.
What deserves attention
- Risk Intelligence — 7 percentile, adding only 2.2 of a possible 30 points.
- Long-Term Potential — 23 percentile, adding only 7.0 of a possible 30 points.
- Ownership Intelligence — 32 percentile, adding only 6.4 of a possible 20 points.
Outside the score
Additional research — not currently included in the primary Suggested Investment Score.
- Valuation Intelligence — SOTERA HEALTH CO reads 57 out of 100 on Valuation Intelligence, recorded as Reasonable. The stock currently trades below most of its own recent valuation history and below comparable companies. This describes the price being paid relative to the company's financials — it is not a forecast and not a fair value.
- Capital Returns Intelligence — SOTERA HEALTH CO reads 29 out of 100 on Capital Returns Intelligence (Limited Capital Returns), reflecting no measurable direct capital returns. Direct capital returns are limited because the company continues reinvesting most of its cash.
Pro Investor Intelligence™
Reported by insiders, large shareholders and professional funds. Shown beside our research, never blended into it.
Loading professional-investor activity…
Stored snapshots only
What changed
Research-score history available since September 2026.
Stored research history does not yet cover a full 30 days comparison for this company.
A change is reported as meaningful at 8 score points, 5 rank places, or any change of research classification. Nothing here is a recommendation to buy or sell.
Learn the metrics on this page
Plain-English definitions, with the formula and the limitations of each measure.
Fifth research lens · outside the score
Valuation Intelligence
Valuation Intelligence
Is today's price reasonable?
Valuation Intelligence is currently researched separately and does not affect the Suggested Investment Score or daily ranking.
57/ 100
Reasonable
RESEARCH MODEL
Excellent coverage
Compared with its history
61
Attractive
Is this company expensive or inexpensive compared with its own history?
Compared with peers
56
Reasonable
How expensive is this stock compared with similar companies?
Earnings & cash flow
44
Elevated
How much financial output does an investor receive relative to the price paid?
Growth-adjusted
69
Attractive
Does the company's growth help justify the valuation investors are paying?
SOTERA HEALTH CO reads 57 out of 100 on Valuation Intelligence, recorded as Reasonable. The stock currently trades below most of its own recent valuation history and below comparable companies. This describes the price being paid relative to the company's financials — it is not a forecast and not a fair value.
Price data through September 11, 2026 · Financial data through the quarter ended June 30, 2026
Valuation history
Stored readings only. The dashed line is this company's own median for the selected measure.
Only one stored valuation reading exists so far, so there is nothing to chart yet. Valuation history builds forward from activation rather than being reconstructed.
Current P/E 32.1x · own median 61.7x · peer median 33.4x
Valuation is inherently uncertain. A stock that appears inexpensive can continue falling, and a stock that appears expensive can continue rising. Valuation Intelligence provides context about the price investors are paying — it does not predict short-term market movements, and it never produces a fair value, a price target or a buy or sell range. Model VALUATION_INTELLIGENCE_V1.
Sixth research lens · outside the score
Capital Returns Intelligence
Capital Returns Intelligence
How effectively does the company reward shareholders?
Capital Returns Intelligence is researched separately and contributes 0% to the Suggested Investment Score, the daily rank or any ranking event.
29/ 100
Limited Capital Returns
RESEARCH MODEL
Good coverage
Dividend Quality
—
Not Applicable — No Dividend
Dividend reliability
This company currently retains rather than distributes cash through dividends. Capital Returns Intelligence therefore places more emphasis on its other measurable shareholder-return behaviors according to the frozen V1 methodology.
Buyback Effectiveness
30
Limited Capital Returns
Do buybacks actually reduce shares?
No net share repurchases are recorded in the stored cash-flow statements.
Dilution Control
30
Limited Capital Returns
Is your ownership share protected?
Capital Return Sustainability
—
Not Available
Can the cash flow support it?
The company returned no measurable capital in the latest period, so there is nothing to sustain.
Shareholder Yield
25
Limited Capital Returns
Cash returned versus company value
SOTERA HEALTH CO reads 29 out of 100 on Capital Returns Intelligence (Limited Capital Returns), reflecting no measurable direct capital returns. Direct capital returns are limited because the company continues reinvesting most of its cash.
This company currently retains rather than distributes cash through dividends. Capital Returns Intelligence therefore places more emphasis on its other measurable shareholder-return behaviors according to the frozen V1 methodology.
No measurable cash was returned to shareholders through dividends or net repurchases in the latest stored statements.
Price data through September 11, 2026 · Financial data through the quarter ended June 30, 2026
Capital returns history
Stored readings only. History builds forward from activation rather than being reconstructed.
Only one stored reading exists for this measure so far, so there is nothing to chart yet.
Why higher yield isn't always better
A very high dividend yield may reflect a falling share price or an unsustainable payout. Capital Returns Intelligence emphasizes consistency and sustainability rather than simply rewarding the highest yield.
Why buybacks can be misleading
Announced or gross buyback spending does not always mean shareholders are gaining ownership. Companies can simultaneously issue shares through employee compensation or acquisitions. Suggested Investments therefore considers actual share-count changes alongside repurchase spending.
What these terms mean
- Dividend Yield
- The annual dividend relative to the current share price.
- Payout Ratio
- The share of company earnings used to pay dividends.
- Free Cash Flow Payout
- How much of the company's available cash is being used for dividends.
- Share Repurchases
- When a company buys back its own stock.
- Dilution
- When the number of shares increases, reducing each existing share's percentage ownership of the company.
- Shareholder Yield
- A combined view of dividends and net share repurchases relative to the company's market value.
Capital Returns Intelligence describes how a company returns capital to shareholders. It is not a measure of stock-price performance, it does not predict future returns, and a strong reading is never a recommendation to buy. Dividends and repurchases can be reduced or stopped at any time. Model CAPITAL_RETURNS_INTELLIGENCE_V1, contributing 0% to the Pro Investor Score.
Stored daily snapshots only
Ranking history
| Today | #636 | Score 26 |
|---|---|---|
| 30 days ago | Not ranked | No stored score |
| 90 days ago | Not ranked | No stored score |
| First suggested | Not yet suggested | |
| Highest rank | #636 | |
In the company’s own words
What this company does
We are a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry. We are driven by our mission: Safeguarding Global Health . We provide end-to-end sterilization as well as microbiological and analytical lab testing and advisory services to help ensure that medical, pharmaceutical and food products are safe for healthcare practitioners, patients and consumers in the United States and around the world. In 2025, our customers included over 40 of the top 50 medical device companies and nine of the top ten global pharmaceutical companies (based on revenue). Our services are an essential aspect of our customers’ manufacturing processes and supply chains, helping to ensure sterilized medical products reach healthcare practitioners and patients. Most of our services are necessary for our customers to satisfy applicable government requirements.
We are a trusted partner to customers in over 50 countries. We strive to give our customers confidence that their products meet regulatory, safety and effectiveness requirements. With our industry-recognized scientific and technological expertise, we help to ensure the safety of millions of patients and healthcare practitioners around the world. Across our 62 facilities worldwide, we have over 3,000 employees who are dedicated to safety and quality.
We are a leading global provider of outsourced terminal sterilization and irradiation services and have provided sterilization services for over 90 years. We offer a globally integrated platform for our customers in the medical device, pharmaceutical, food safety, and advanced applications markets, with facilities strategically located to be convenient to our customers’ manufacturing sites and distribution hubs or routes.
Terminal sterilization is the process of sterilizing a product in its final packaging; it is an essential, and often government-mandated, last step in the manufacturing process of healthcare products before they are shipped to end-users. The products that we sterilize include procedure kits and trays, implants, syringes, catheters, wound care products, medical protective barriers, including personal protective equipment ("PPE"), laboratory products and pharmaceuticals.
Quoted from the business section of this company’s 10-K filed February 24, 2026. Read the filing
Four distinct intelligence areas
The IA view
Risk Intelligence
Production core
53
Fundamentally Qualified
No prior period to compare
Business Quality qualification score from the locked IA Defensive Research Core. Price Risk stays a separate category and is never blended in.
As of Sep 11, 2026
Long-Term Potential
Research model
43
Weak Compounder
No prior period to compare
Durable business economics and reinvestment characteristics. Independent external validation is pending.
As of Sep 11, 2026
Fundamental Momentum
Research model
53
Middle
No prior period to compare
Direction and breadth of change in underlying business fundamentals. Not a price-momentum signal.
As of Sep 11, 2026
Elite Investor Activity
Supplemental
—
Insufficient Data
No prior period to compare
Too few tracked managers disclosed a position to describe consensus.
Intelligence history
Not enough stored history to chart SHC yet. A company needs at least two published research or ownership periods before a trend can be shown.
Share price
SHC price history
Closing prices adjusted for splits and dividends. Past prices do not indicate future results.
- 6M change
- +35.4%
- 1Y change
- +12.7%
- 3Y change
- +23.9%
- 5Y change
- -26.3%
- Max change
- -26.8%
Last stored close $18.37 · +12.7% over the selected range · 63 sessions shown
Balanced evidence
Why IA likes it
- More disclosed holders are new or increasing than reducing or exiting.
Risk and uncertainty
What IA doesn’t like
- No specific negative evidence is available. This is not evidence of low risk.
What would change our view
- Business Quality falling below the frozen qualification threshold.
- Price Risk moving to a less favorable category.
- A sustained reversal in the Fundamental Momentum research evidence.
- New material public ownership disclosures.
Public filings · descriptive only
Elite Investor Activity
Reporting holders
4
New holders
3
Increasing
0
Reducing
1
Exiting
0
Coverage
Excellent
Positive disclosed activity · Report period 2022-12-31 · Public 12/19/2023
| Manager | Change | Portfolio weight | Rank | Disclosed |
|---|
Insufficient high-confidence manager coverage.
Objective stored changes
What changed
No qualifying changes are recorded for this company in the stored research and filing history.
Ownership timeline
No high-confidence public ownership events are available.
General research only. Not personalized advice. Public filings may be delayed, amended, incomplete, or reflect positions that have changed since the reporting date.